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Introduction 
The role of small airway inflammation in asthma has 
received much attention in recent years (l-3). This review 
discusses the targets of inhaled corticosteroid asthma 
medication, highlighting the aerosol characteristics required 
to achieve deposition of drug throughout the airways of the 
lung, including the small airways. 
GRs are ubiquitously distributed throughout the lung, 
with a higher density found in the alveolar walls and 
endothelium and the smooth muscle of the bronchial 
and pulmonary vessels (13). Smaller numbers of GRs are 
found in the upper airway epithelium and smooth muscle. 
Since there is evidence of a high density of GRs in’ the 
alveoli, it seems reasonable to include this site as a likely 
target for inhaled corticosteroids. In order to reach all GRs 
it is clearly important to deliver medication to small, 
medium and large airways. 
Airway inflammation in asthma 
Airway inflammation is the basic underlying abnormality in 
asthma and is apparent in all asthma severities (4). Deposition mechanisms 
Inflammation is present throughout the lung, affecting 
both the large and small (internal diameter <2 mm) 
airways (5). However, the inflammation that occurs in the 
small peripheral airways may be more severe than that seen 
in the large central airways (6). In addition, inflammation in 
the alveolar compartment, as indicated by increased 
numbers of CD4+ T-lymphocytes, appears to be particu- 
larly associated with nocturnal asthma (7,8). 
The aim of any asthma therapy is to prevent and reverse 
airway inflammation. At present, inhaled corticosteroids 
such as beclomethasone dipropionate (BDP), are the most 
effective anti-inflammatory agents available for the treat- 
ment of asthma (4). Inhalation, for example via a 
pressurized metered dose inhaler (pMDI), is the most 
common method of administrating these agents. Delivery 
via the inhaled route often uses a nominal dose, achieves a 
high local airway concentration, results in a quicker 
response, and produces fewer systemic side effects than 
oral administration (9). 
Glucocorticoid receptors 
Corticosteroids act by binding to glucocorticoid receptors 
(GRs) that are found in the cellular cytoplasm (10). The 
mechanism of genomic action is complex and has been 
reviewed previously (10-12). In brief, the effect of 
corticosteroids starts with the activation of the GR to 
increase or decrease transcription of various target genes 
linked with chronic inflammatory processes. 
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There are three deposition mechanisms that act concur- 
rently on aerosol particles; inertial impaction, gravitational 
sedimentation and Brownian diffusion. For a given breath- 
ing pattern and lung morphology, the different fraction of 
the aerosol, based on particle size and density, will be acted 
upon by the three lung deposition mechanisms to different 
degrees. 
The logarithms of the particle sizes in an aerosol from an 
MD1 are normally distributed (14). They can be defined by 
the following equation (15): 
In MMAD = In CMD + 3(ln GSD)’ 
where the mass median aerodynamic diameter (MMAD) is 
the aerodynamic diameter above and below which 50% of 
the mass of particles within the aerosol are contained, the 
count median diameter (CMD) is the diameter above and 
below which 50% of the total number of particles within 
the aerosol are contained, and the geometric standard 
deviation (GSD) is the range of distribution of aerosol 
particle size around the median. 
For MDIs, cascade impactors give a direct measure of 
the MMAD and GSD. The aerodynamic parameter is most 
commonly used to describe pharmaceutical aerosols, 
however, it should be remembered that the CMD distribu- 
tion is markedly skewed towards much smaller particle 
sizes. This may well be important therapeutically. For 
aerosols with an MMAD of between 0.5 and 5pm, 
deposition in the tracheobronchial airways will be due to 
impaction and sedimentation, whereas deposition in the 
lower airways will be due to sedimentation and Brownian 
diffusion. Which deposition mechanism (and, therefore, 
site of deposition) predominates depends primarily on 
particle size. For larger particles, movement by gravita- 
tional sedimentation is most important. For particles 
smaller than O.Spm, Brownian diffusion becomes a more 
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appropriate explanation for deposition mechanism than 
sedimentation, and as particle size decreases, the particles 
are able to travel further by this mechanism of diffusion: 
When considering the design of an aerosol plume, both 
the MMAD and GSD should be taken into consideration. 
If two MDIs have the same MMAD but a different GSD, 
or vice versa, modelling shows that they will have a 
different lung deposition profile (16). Changes in both 
measures of particle size are likely to affect the dose to the 
target tissues and the site of drug deposition in the airways 
(16). 
The overall cross-sectional surface area of the airways 
increases towards the periphery of the lung (17). As the 
surface area increases, the flow of air decreases. At the 
terminal bronchioles there is no airflow and small particles 
of drug may move into the alveoli by the process of 
Brow&n diffusion (Fig. 1). 
.tion into the Inhaled drug deposi 
airways 
Since GRs are found throughout the airways it is important 
to distribute the drug throughout the lung, including the 
peripheral airways. The design of any inhaler device/ 
corticosteroid combination should strive to achieve this 
distribution. Therefore, the delivery profile of an inhaled 
corticosteroid into the tracheobronchial tree is an impor- 
tant characteristic with likely therapeutic consequences. 
Particles of less than Sprn have been termed ‘respirable’ 
(9) as they are more likely to distribute further than the 
upper airways, resulting in tracheobronchial and pulmon- 
ary distribution (18). Less deposition of inhaled drug occurs 
in the upper respiratory tract and more in the airways of the 
lower respiratory tract as MMAD decreases (19). There- 
fore, the probability of a particle penetrating the tracheo- 
bronchial tree is correlated with MMAD. The smaller the 
MMAD, the further down the tracheobronchial tree the 
drug particle is likely to deposit (Fig. 2). Furthermore, for a 
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FIG 1. Surface area increases and air flow decreases 
towards the periphery of the lung, resulting in respirable 
steroid particles reaching all inflamed airways and 
glucocorticoid receptors. 
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FIG 2. The deposition of particles of varying sizes down 
the tracheobronchial tree. 
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FIG 3. Percentage of inhaled dose of HFA-BDP and 
xenon deposited in the peripheral, intermediate, and 
central regions of the right and left lungs of healthy 
volunteers. 0: HFA-BDP, 1: Xenon. (Leach CL, 
Davidson P, Boudreau R. Poster presented at World 
Asthma Meeting, Barcelona, Spain, IO-30 December 
1998.) 
given respirable mass, the number of particles in the dose 
increases exponentially as the MMAD decreases. The 
greater number of small particles facilitates more even 
distribution as the aerosol cloud is inhaled and transported 
through the many bifurcations from the central to the 
peripheral airways. 
Hydrofluoroalkane-l34a (HFA)-BDP extrafine aerosol 
(QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.) has 
a smaller average MMAD (1.1 pm) than conventional 
chlorofluoiocarbon (CFC)-BDP (3.5pm) (20). Due to the 
smaller mass and, therefore, momentum of the HFA-BDP 
particles, HFA-BDP is delivered with a considerably lower 
impact force compared with CFC-BDP (21). This softer 
spray results in less undesirable throat deposition with 
HFA-BDP than with CFC-BDP. The plume from the 
HFA-BDP MD1 is also warmer (approximately 3°C) than 
CFC-containing MDIs (as low as - 3O”C), thus minimizing 
the likelihood of the patient experiencing the ‘cold-freon’ 
effect, which can prevent the patient inhaling the product 
sufficiently (21). These factors may explain the increased 
total lung deposition (with consequent decreased orophar- 
yngeal deposition) seen with HFA-BDP compared with 
CFC-BDP. In healthy subjects, the mean percentage lung 
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deposition of radiolabelled HFA-BDP was 55% compared 
with 4% with CFC-BDP (20). This study also demonstrated 
that, in patients with asthma, 56% of a dose of 
radiolabelled HFA-BDP was deposited in the lungs. 
Further, the distribution of xenon-133 gas (used as an 
indicator of maximum lung dispersion) was similar to that 
of HFA-BDP, indicating that the distribution of HFA- 
BDP throughout the lung is virtually optimal (Fig. 3). 
Clinical studies have confirmed the therapeutic benefits of 
improved lung deposition. A dose-response study compar- 
ing HFA-BDP with CFC-BDP (both at 100, 400 and 
800 gg day- ‘) demonstrated that HFA-BDP provided 
equivalent asthma control at less than half the daily dose 
of CFC-BDP (22). HFA-BDP had equivalent efficacy at a 
2.6-fold lower dose than CFC-BDP with regard to FEVi 
percentage predicted and at a 3.2-fold lower dose than 
CFC-BDP with regard to FEFzs7s%. 
Computed tomographic scanning 
Airway resistance in the small airways is very low and is 
estimated to be about 10% of the total (23). This means 
that inflammation in the small airways is not easily detected 
by conventional measures of assessing lung function and, 
particularly during the early stages of asthma development, 
may not manifest itself as measurable symptoms (23). From 
a study of patients with newly diagnosed asthma, Laitinen 
et al. (24) concluded that airway inflammation exists even at 
the early presentation of asthma. 
Computed tomographic (CT) scanning captures fine 
details of the airways of the lung (25,26) and may be able 
to show subtle differences, particularly in the small airways, 
that are not readily identified by conventional measures of 
pulmonary function. For example, a recent double-blind 
randomized study showed HFA-BDP to have greater 
efficacy in the peripheral airways than CFC-BDP as 
assessed by functional high resolution CT imaging techni- 
ques (27). 
Conclusion 
GRs are key targets for inhaled therapy as they are involved 
in modulation of the inflammatory process that occurs in 
asthma. They are located throughout the airways of the 
lung, including the alveoli. A small aerosol particle size of 
an inhaled corticosteroid, for example 1 pm as seen with 
HFA-BDP extrafine aerosol, appears to have the optimum 
characteristics for reaching the entire tracheobronchial tree 
including the small airways. This, in turn, should lead to a 
favourable efficacy profile, since the active drug is presented 
as an aerosol designed to reach all of the desired 
inflammatory targets in the airways. 
References 
1. Evans DJ, Green M. Small airways: a time to revisit? 
Thorax 1998; 53: 629-630. 
2. Howarth P. Small airway inflammation and asthma. 
Int J Clin Pruct 1998; 96 (Suppl. 96): 15-22. 
3. Roche WR. Inflammatory and structural changes in 
the small airways in bronchial asthma. Am J Respir 
Crit Care Med 1998; 157: S191-S194. 
4. Global Initiative for Asthma: global strategy for 
asthma management and prevention. Bethesda, MD: 
Natonal Heart, Lung, and Blood Institute, National 
Institutes of Health NHLBI/WHO workshop report, 
1995; Publication No. 95-3659. 
5. Howarth P. The relevance and site of airway inflam- 
mation in asthma and targeted aerosol delivery. Int J 
Clin Pratt 1999; (Suppl. 106): 3-10. 
6. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation 
of small airways in asthma. J Allergy Clin Immunol 
1997; 100: 44-51. 
7. Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin 
RJ. Alveolar tissue inflammation in asthma. Am J 
Respir Crit Cure Med 1996; 154: 1505-1510. 
8. Kraft M, Vianna E, Martin RJ, Leung DYM. 
Nocturnal asthma is associated with reduced gluco- 
corticoid receptor binding affinity and decreased 
steroid responsiveness at night. J Allergy Clin Immunol 
1999; 103: 66-71. 
9. Laube BL. In vivo measurements of aerosol dose and 
distribution: clinical relevance. J Aerosol Med 1996; 9 
(Suppl. 1): s77-s91. 
10. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety 
of inhaled corticosteroids. Am J Respir Crit Care Med 
1998; 157: Sl-S53. 
11. van der Velden VH. Glucocorticoids: mechanisms of 
action and anti-inflammatory potential in asthma. 
Mediators Infiamm 1998; 7: 229-237. 
12. Jaffuel D, Mathieu M, Godard P, Michel FB, Demoly 
P. Mechanism of action of glucocorticoids in asthma. 
Rev Mal Respir 1999; 16: 431-442. 
13. Adcock IM, Gilbey T, Gelder CM, Chung KF, Barnes 
PJ. Glucocorticoid receptor localization in normal and 
asthmatic lung. Am J Respir Crit Care Med 1996; 154: 
77-182. 
14. Martonen TB. Aerosol therapy implications of particle 
deposition patterns in simulated human airways. J 
Aerosol Med 1991; 4: 25-40. 
15. Raabe OG. Particle size analysis utilising grouped data 
and the log-normal distribution. J Aerosol Sci 1971: 2: 
289 
16. Martonen TB, Katz J. Deposition patterns of poly- 
disperse aerosols within human lungs. J Aerosol Med 
1993; 6: 251-274 
17. Weibel ER. Morphometry of the Human Lung. New 
York: Academic Press. 1963. 
18. Newman SP, Woodman G, Clarke SW. Deposition of 
carbenicillin aerosols in cystic fibrosis: effects of 
nebuliser system and breathing pattern. Thorax 1988; 
43: 318-322. 
19. Newhouse MT. The current laboratory determination 
of “respirable mass” is not clinically relevant. J Aerosol 
Med 1998; 11 (Suppl. 1): S122-S132. 
20. Leach CL. Effect of formulation parameters on 
hydrofluoroalkane-beclomethasone dipropionate drug 
516 8. J. h’W0Rl-H 
deposition in humans. J Allergy Clin Immunol 1999; 
104: s250-s252. 
21. Gabrio BJ, Stein SW, Velasquez DJ. A new method to 
evaluate plume characteristics of hydrofluoroalkane 
and chlorofluorocarbon metered dose inhalers. Int J 
Pharmaceut 1999; 186: 3-12. 
22. Busse WW, Brazinsky S, Jacobson K. Efficacy response 
of inhaled beclomethasone dipropionate in asthma is 
proportional to dose and is improved by formulation 
with a new propellant. J Allergy Clin Immunol 1999; 
104: 1215-1222. 
23. Green M. Treating large and small airways. Int J C/in 
Pratt 1998; 96 (Suppl. 96): 2-4. 
24. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal 
inflammation even in patients with newly diagnosed 
asthma. Am Rev Respir Dis 1993; 147: 697-704. 
25. Grenier P, Mourey-Gerosa I, Benali K, et al. Abnorm- 
alities of the airways and lung parenchyma in 
asthmatics: CT observations in 50 patients and inter- 
and intraobserver variability. Eur Radio/ 1996; 6: 199- 
206. 
26. Awadh N, Muller NL, Park CS, Abboud RT, 
FitzGerald JM. Airway wall thickness in patients with 
near fatal asthma and control groups: assessment 
with high resolution computed tomographic scanning. 
Thorax 1998; 53: 248-253. 
27. Goldin JG, Tashkin DP, Kleerup EC, et al. Compara- 
tive effects of HFA- and CFC-beclomethasone 
diproprionate inhalation on small airways: Assess- 
ment using functional helical thin-section com- 
puted tomography. J Allergy C/in Immunol 1999; 
104: S258-S267. 
